[Yung Shin] Announcement of the Approval of Non-Compete Restriction Removal for Directors at the 2026 Annual General Meeting
NQ Score
46/100
N1 Content Completeness
10
AI Summary (NQ-processed)
Yung Shin Pharmaceutical announced that the 2026 AGM approved the removal of non-compete restrictions for three directors. Director Li Fang-chuan will hold a concurrent position at De-Zhen Pharmaceutical (Jiangsu) Co., Ltd., with no material impact on the company's finances.
AI Analysis
Frequently Asked Questions
- Q: What is Article 209 of the Taiwan Company Act?
- A: It requires directors to obtain shareholder approval before engaging in competitive business activities that overlap with the company's scope.